Source comparison
CJC-1295 no DAC & Ipamorelin: Peptide Type Comparison
The pharmacological profiles of CJC-1295 no DAC and Ipamorelin differ in mechanism, receptor selectivity, half-life, and side effect profile. Understanding these distinctions clarifies why combination protocols produce synergistic effects without redundancy. C
This comparison does not assign a generated winner or score.
- The pharmacological profiles of CJC-1295 no DAC and Ipamorelin differ in mechanism, receptor selectivity, half-life, and side effect profile. Understanding these distinctions clarifies why combination protocols produce synergistic effects without redundancy.
- CJC-1295 no DAC
- GHRH analog. Amplifies endogenous GHRH signaling by extending receptor occupancy time
- GHRH receptor (pituitary somatotrophs)
- 30 minutes (vs 7 min for native GHRH)
- 8–12 ng/mL at 30–45 min post-dose
- Minimal. No cortisol or prolactin elevation
- Best for researchers seeking physiological GH pulsatility without long-acting DAC modification
- Ipamorelin
- Selective ghrelin mimetic. Stimulates GH release via ghrelin receptor pathway independent of GHRH
- GHS-R1a (growth hormone secretagogue receptor)
- Approximately 2 hours
- 6–10 ng/mL at 20–30 min post-dose
- None detected. No cortisol, ACTH, or prolactin increase
- Most selective secretagogue available. Ideal for isolating GH effects without confounding hormone changes
- CJC-1295 with DAC
- GHRH analog with Drug Affinity Complex extending half-life to 6–8 days
- 6–8 days
- Sustained elevation 4–6 ng/mL baseline
- Potential for desensitization with chronic use
- Avoided in research requiring washout flexibility or pulsatile GH patterns
- GHRP-6
- Non-selective ghrelin mimetic. Earlier-generation secretagogue
- GHS-R1a plus cortisol and prolactin pathways
- 15–60 minutes
- 10–15 ng/mL but with cortisol co-elevation
- Significant appetite stimulation, cortisol increase, prolactin increase
- Superseded by Ipamorelin due to poor selectivity
- Combination protocols pair CJC-1295 no DAC with Ipamorelin to exploit dual-pathway stimulation: GHRH receptor activation from one angle, ghrelin receptor activation from another, producing GH pulses 30–50% larger than either compound alone without extending half-life into the multi-day range that complicates protocol timing and washout scheduling.